China Registration Study in Patients With Skin Infections

Model scores of the 29,894 trials active now.

Model score 17% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (876 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2010-09-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: subjectsinfectionsinfectionintravenouspositive
  Phrases that lowered it: siteefficacycompared withrandomisedevaluate
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 6.1% (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 282 (raises risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Phase: 3 (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports with a death: 22.6% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Blinding: single (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 89.5% (raises risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Sponsor's past trials: 474 (lowers risk) · Sponsor's track record
• Drug's FAERS reports before start: 4896 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections NCT01499277 · started 2012 · scored riskier than 94% of active trials completed
• Evaluation of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections. NCT02202135 · started 2014 · scored riskier than 49% of active trials terminated
• Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections NCT01184872 · started 2010 · scored riskier than 41% of active trials completed
• Efficacy and Safety Study of JNJ-32729463 for Treating Complicated Skin and Skin Structure Infections Compared to Linezolid (Zyvox) NCT01128530 · started 2010 · scored riskier than 34% of active trials completed
• Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI) NCT03405064 · started 2017 · scored riskier than 20% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.